California law surrounding innovative new biologic and biosimilar medications has returned for the 2015-2016 session.
Because of the complexity of creating these drugs, it is virtually impossible to create identical “generic” products of biologics. Instead, biologics have what are called biosimilar or interchangeable biological products that meet varying degrees of similarity. This is especially important today with the introduction of interchangeable biologics into state markets continuing to grow closer.